Main competitors
Add to a list
1m. EPS revision 1m. Revenue rev. 4m. EPS revision 4m. Revenue rev. 1y. EPS revision 1y. Revenue rev. Divergence of Estimates Nbr of analysts
16
30
24
16
20
17
22
24
- - - - - - 7
16
21
- - - 9
22
24
- - - -
15
5
11
15
18
Average 17
Weighted average by Cap. 22
Bio Therapeutic Drugs